Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01192906 · ClinicalTrials.gov registry record · Phase 3

A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)

A Phase 3 study of Schizophrenia, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 3
Development phase
624
Enrollment target
20
Study locations

NCT01192906 is a Phase 3 study of Schizophrenia that has completed, run by Hoffmann-La Roche. The registered enrollment target is 624 participants, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (188% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01192906, a Phase 3 study of Schizophrenia, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 3
Development phase
624 participants
Enrollment target
20
Study locations

Study Summary

This multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with persistent, predominant negative symptoms of schizophrenia. Patients, on stable treatment with antipsychotics, will be randomized to receive daily oral doses of RO4917838 or matching placebo for 52 weeks, followed by an optional treatment extension for up to 3 years.

Conditions Studied

Schizophrenia

Interventions

  • DRUG Placebo
  • DRUG bitopertin [RO4917838]

Study Locations (20)

California

  • - Carson
  • - Oceanside
  • - San Diego
  • - San Diego

Illinois

  • - Chicago
  • - Hoffman Estates
  • - Joliet

New York

  • - Cedarhurst
  • - Jamaica
  • - Rochester

Connecticut

  • - Hartford
  • - Norwalk

Louisiana

  • - Lake Charles
  • - Shreveport

Pennsylvania

  • - Allentown
  • - Norristown

Florida

  • - North Miami

Georgia

  • - Atlanta

Trial Details

FieldValue
Enrollment Target 624 participants
Start Date 2010-12
Est. Completion 2014-07
Phase Phase 3

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01192906

The ClinicalTrials.gov registry entry for NCT01192906 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 624 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (188% higher). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01192906 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Illinois, New York.

Frequently Asked Questions

What is clinical trial NCT01192906 about?

NCT01192906 is a clinical study titled "A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)". This multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with persistent, predominant negative symptoms of schizophrenia. Patients, on stable treatment with antipsychotics, will be randomized to ...

What is the current status of trial NCT01192906?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 624 participants. The study started on 2010-12. Estimated completion is 2014-07.

What conditions does trial NCT01192906 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT01192906?

The interventions under investigation include: Placebo (DRUG), bitopertin [RO4917838] (DRUG).

Who is sponsoring clinical trial NCT01192906?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01192906 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.